News
Hypertension affects 1 in 3 adults globally and is the leading modifiable risk factor for cardiovascular disease. Aldosterone ...
2d
MyChesCo on MSNMineralys Therapeutics Publishes Phase 3 Trial Results in JAMA for Hypertension TreatmentRADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced the publication of groundbreaking results from its pivotal Phase 3 Launch-HTN trial in the Journal of the American Medical ...
Objectives To explore patients’ and healthcare practitioners’ (HCPs) views about non-adherence to hypertension medication and potential content of a combined very brief face-to-face discussion (VBI) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results